A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are now.

Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their medications elsewhere.

Some commercially insured patients stand to save $150 per month on Wegovy, a popular obesity medication. Patients on Medicare and Medicaid are not eligible.

State DHS officials say new weight-loss drugs are driving up costs for Pennsylvania’s Medicaid program, likely leading to more than $1 billion in new costs this year.

Very few people are currently being prescribed drugs for weight loss on the NHS in Scotland, research by BBC Scotland News has established. Medications like Mounjaro and Wegovy have been hailed as "game changers" for tackling obesity.

Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available after a decision by the U.S. Food and Drug Administration. The agency has ordered compounding pharmacies to stop making compound versions of GLP-1 drugs now that the drugs are no longer in short supply.